{"id":"NCT00848120","sponsor":"Hoffmann-La Roche","briefTitle":"A Study to Assess the Effect of Tocilizumab on Signs and Symptoms in Patients With Rheumatoid Arthritis","officialTitle":"An Open Label Study to Evaluate the Safety and Reduction in Signs and Symptoms During Treatment With Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-12-31","primaryCompletion":"2010-02-13","completion":"2010-02-13","firstPosted":"2009-02-20","resultsPosted":"2015-01-07","lastUpdate":"2017-08-03"},"enrollment":29,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"tocilizumab [RoActemra/Actemra]","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"}],"summary":"This single arm, open label study will assess the safety and efficacy, with regard to reduction of signs and symptoms,of treatment with tocilizumab in patients with moderate to severe active rheumatoid arthritis. Patients will receive tocilizumab 8 mg/kg IV every 4 weeks for a total of 6 infusions. Patients already receiving methotrexate at entry into the study may continue with their treatment together with tocilizumab.The anticipated time on study treatment is 3-12 months, and the target sample size is \\<100 individuals.","primaryOutcome":{"measure":"Percentage of Participants Achieving American College of Rheumatology (ACR) 20 Percent (%) Improvement (ACR20 Response) at Week 24","timeFrame":"Week 24","effectByArm":[{"arm":"Tocilizumab 8 mg/kg","deltaMin":86,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":3},"locations":{"siteCount":4,"countries":["Philippines"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":29},"commonTop":["Elevated AST/SGOT level","Elevated ALT/SGPT level","Elevated AST ad ALT levels","Urinary tract infection (UTI)","Upper respiratory tract infection"]}}